Kathryn A. Lurain, M.D., M.P.H.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 6N110
- Bethesda, MD 20892-1868
- 240-858-3257
- kathryn.lurain@nih.gov
RESEARCH SUMMARY
Dr. Lurain is an Associate Research Physician in the HIV/AIDS Malignancy Branch. She is an expert in the treatment of a variety of HIV-associated cancers, including those caused by Kaposi sarcoma herpesvirus (KSHV). Her clinical research is focused on the development of new immunotherapy-based treatments for HIV-associated lymphomas and other virus-associated cancers. Dr. Lurain is an advocate for people living with HIV and their inclusion in clinical trials. She is trained in the clinical care of sexual and gender minorities.
Areas of Expertise
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Kathryn A. Lurain, M.D., M.P.H.
Clinical Trials
Research
Dr. Lurain is a hemato-oncologist within the HIV/AIDS Malignancy Branch. She developed the first prospective clinical trial in primary effusion lymphoma (PEL) combining standard chemotherapy with the immunomodulatory drug, lenalidomide. She has helped elucidate the unique natural history of PEL compared to other HIV-associated lymphomas and identified human interleukins 6 and 10 and the EBV status of the tumor as prognostic markers in this rare disease. Her translational work focuses on understanding the changes in cellular and humoral immune function at the onset of KSHV-associated conditions and how immune function is affected by treatment.
Publications
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
Biography
Kathryn A. Lurain, M.D., M.P.H.
Dr. Lurain earned her Bachelor of Arts in Biology from Oberlin College and Masters in Global Public Health from the George Washington University School of Public Health. She received her M.D. from the University of Virginia School of Medicine and completed her residency in internal medicine at the University of Chicago Medical Center. She completed her fellowship in hematology and oncology at the National Cancer Institute and joined the HIV/AIDS Malignancy Branch as faculty in 2018. She is the associate program director for hematologic malignancies and DEIA initiatives for the NIH hematology-oncology fellowship.
